Aventis Pharma S.a.

Centre National De La Recherche Scientifique

Rhone-Poulenc Rorer S.a.

Other

Sanofi-Aventis

Assistance Publique-Hopitaux De Paris

Sorbonne Université

Institut National De La Sante Et De La Recherche Medicale (Inserm)

Institut Du Cerveau Et De La Moelle Epiniere

Centelion Sas

Institut National De Recherche Pour L'agriculture, L'alimentation L'environnement

Universitè De Montpellier

Université Pierre Et Marie Curie

Inserm

Jacques Mallet

Fr&eacute;d&eacute;ric Revah

Michel Perricaudet

Axel Kahn

Jean-Jacques Robert

Chamsy Sarkis

Emmanuelle Vigne

Jean-Marie Stutzmann

Martine Barkats

Philippe Ravassard

Frederic Revah

Gildas Le Gal La Salle

Frédéric Revah

Sylvie Berrard

Alain Privat

Fran&ccedil;oise Finiels

Minerva Gimenez-Ribotta

Marc Abitbol

Jean-Philippe Hugnot

Che Serguera

Marc Peschanski

Rolando Meloni

Fabienne Treilhou

Noelle Dufour

Philippe Horellou

Riccardo Cervini

Stephanie Philippe

Claudine Laurent

Tania Smirnova

Yi He

Pierre Fafournoux

Christine Icard-Liepkalns

Jean-Luc Ridet

St&eacute;phane Bejanin

Stéphanie Millecamps-Navarro

Stéphanie Philippe

Georg Haase

Philippe Kennel

Marie José Lecomte

Paul Roustan

Julie Santamaria

Pierre-Olivier Guichet

A nucleic acid for the controlled expression of a nucleic acid encoding a pro-apoptotic protein in an individual, including: a regulatory polynucleotide including a minimal promoter and at least one AARE (amino acid response element) nucleic acid, the regulatory polynucleotide being activated in an individual upon consumption of a diet deficient in at least one essential amino acid; and a nucleic acid encoding a pro-apoptotic protein, which is placed under the control of the regulatory polynucleotide.

Diet controlled expression of a nucleic acid encoding a pro-apoptotic protein

The present invention relates to pharmaceutical compositions that act on the p53 protein or its gene and methods of use for the treatment of neurodegenerative diseases.

Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases

The invention concerns a non-integrative and non-replicative recombinant lentivirus as well as its uses, in particular for preparing a composition for transferring genes in vitro, ex vivo or in vivo. The invention is useful for transferring genes in any mammal organism, for example in liver, muscle, pancreas or central nervous system (including the ocular sphere) tissues or cells, and in particular for treating disorders or pathologies such as, for example, central nervous system, including the ocular sphere, disorders.

Non-integrative and non-replicative lentivirus, preparation and uses thereof

The present invention relates to nucleic acid sequences producing at least one functional miRNA, at least one functional shRNA and/or at least one functional siRNA, said miRNA, shRNA or siRNA being designed to silence the expression of a gene that encodes a cholinergic protein. The present invention further relates to compositions and kits comprising such nucleic acid sequences as well as to uses thereof.

RNAi mediated expression inhibition of a cholinergic protein

The invention relates to a defective lentivirus which is pseudotyped with a lyssavirus envelope of the PV (rabies virus) or MOK type (Mokola virus), for example, and to the use thereof, especially in the preparation of a composition for in vivo transfer of genes in astrocytes and also for the treatment of disorders of the central nervous system.

Methods of gene transfer to astrocytes with mokola virus pseudotyped lentivirus vectors

The present invention is related to compositions and methods for the delivery of nucleic acids to neurons in a mammal, and uses thereof. The present invention specifically discloses the use of compounds that cause synaptic nerve sprouting to increase neuron retrograde transport of a vector or a product (a polypeptide or a nucleic acid for example) in a mammal. The invention is also based on the use of a compound that interacts with synaptosomal associated proteins to increase neuron retrograde transport of a vector or a product such as one cited above in a mammal. The invention also relates to a product comprising a viral vector comprising a transgene and a compound that causes synaptic nerve sprouting, for sequential use for delivering said transgene to neurons by retrograde transport and its uses for the preparation of a composition used as a treatment in several neurological disorders. The methods and compositions of this invention can be used to deliver various transgenes, such as markers, vaccines, therapeutic genes etc., and are suitable for experimental, therapeutic or various other applications.

Neuronal gene transfer of adenovirus and herpes virus vectors

Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative disorders

The present invention relates to a defective adenovirus comprising at least a DNA sequence coding for all or an active part of glutathione peroxidase or a derivative thereof. It also relates to their utilization in therapy and to the corresponding pharmaceutical compositions.

Adenovirus comprising a gene coding for glutathione peroxidase

The invention concerns novel recombinant viruses and their use for gene-transfer into nerve cells of vertebrates. The invention also concerns pharmaceutical compositions comprising said recombinant viruses. More particularly, the invention concerns novel vectors derived from baculoviruses and their use for treating diseases of the nervous system of vertebrates.

Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates

The present invention relates to nucleic acids that encode novel basic helix-loop-helix polypeptides. The present invention also relates to novel basic helix-loop-helix polypeptides, in particular, rat Relax and human ngn3 polypeptides. The invention also relates to methods for the detection of nucleic acids and polypeptides according to the invention. The invention also relates to methods for the detection of activators or inhibitors of the polypeptides of the invention. Finally, the present invention relates to methods of prevention and/or treatment of pathologies, dysfunctions, disorders or conditions affecting the nervous system.

Polypeptides of the 'basic helix-loop-helix' bHLH family, corresponding nucleic acid sequences

The invention provides an essentially pure preparation of human adult astrocytes, and a method of producing same. The purified astrocytes are useful for the treatment of neurodegenerative disorders or trauma to the central nervous system.

Human adult astrocytes, their preparation and uses thereof

The invention concerns a recombinant DNA vector characterized in that it is capable of directing the expression an/or transcription of a selected nucleotide sequence in the cells of the central nervous system and in that it comprises (i) at least part of the genome of an adenovirus, including the regions required for that adenovirus to penetrate into the cells normally infectable by that adenovirus and (ii) being inserted into said part of genome of an adenovirus under the control of a promoter, either present or also inserted into said genome part and operative in said cells. This recombinant vector finds particular use in the treatment of diseases of the central nervous system, also in gene therapy.

Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain

The invention concerns a novel method for treating motor neuron diseases and particularly amyotrophic lateral sclerosis. It consists more particularly in the systemic administration of expression systems of neurotrophic factors.

Method for treating amyotrophic lateral sclerosis

Recombinant adenoviruses comprising a heterologous DNA sequence coding for basic blast growth factors (bFGF), preparation and uses thereof for the treatment and/or prevention of neurodegenerative diseases.

Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF)

The present invention relates to methods and compositions for delivering a nucleic acid to motor neurons administering the nucleic acid to muscle tissue. The invention relates to methods for treating pathologies of the nervous system, such as trauma and neurodegenerative diseases.

Adenoviral-vector-mediated gene transfer into medullary motor neurons

Growing community of inventors

Paris, France

Jacques Mallet